Publications

Authors:

Argyriou, Andreas A; Karteri, Sofia; Bruna, Jordi; Mariotto, Sara; Simo, Marta; Velissaris, Dimitrios; Kalofonou, Foteini; Cavaletti, Guido; Ferrari, Sergio; Kalofonos, Haralabos P

Title:

Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study

Year:

2022

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

SUPPORTIVE CARE IN CANCER

ISSN of journal:

0941-4355

N° Volume:

30

Number or Folder:

2

Page numbers:

1807-1814

Keyword:

Biomarker; Chemotherapy-induced cognitive impairment; Prediction; Serum neurofilament light chain

Short description of contents:

Objective: To prospectively assess the utility of serum neurofilament light chain (sNfL) levels in identifying the risk to develop chemotherapy-induced cognitive impairment (CICI) in cancer patients. We also examined if sNfL can be identified as an early biomarker of CICI development. Methods: We longitudinally measured sNfL levels in 20 female patients with breast cancer, scheduled to receive the 12 weekly paclitaxel-based regimen. An equal number of age-matched female heathy subjects was incuded as control group. CICI was graded by means of the Montreal Cognitive Assessment scale (MOCA); peripheral neurotoxicity (PN) was graded using the neurosensory Common Criteria for Adverse Events (CTCAE)v5.0, while sNfL levels were quantified using a high-sensitive technique (Quanterix, Simoa) before the administration of chemotherapy (T0), after 3 courses (T1), and at the end of chemotherapy (T2). Results: Pre-treatment sNfL levels were comparable in patients and controls (p = 0.103). At T2, 5/20 patients (mean age 61.4 ± 5.0 years) developed CICI. These 5 patients also had clinically-significant PN. Patients with and without CICI had comparable sNfL values at T2 (p = 0.1). In addition, at T2, sNfL levels did not correlate significantly with MOCA score in CICI patients (p = 0.604). The difference of sNfL levels between T1 and T0 failed to predict independently the occurrence of CICI at T2. Conclusion: Our findings do not support the utility of measuring sNfL levels as a biomarker of CICI. Grade 2-3 PN most strongly confounded our outcomes. Considering the small sample size, which might have prevented the results from being extrapolated, further testing in larger studies is warranted.

Web page:

https://doi.org/10.1007/s00520-021-06509-x

Product ID:

122997

Handle IRIS:

11562/1050982

Last Modified:

November 15, 2022

Bibliographic citation:

Argyriou, Andreas A; Karteri, Sofia; Bruna, Jordi; Mariotto, Sara; Simo, Marta; Velissaris, Dimitrios; Kalofonou, Foteini; Cavaletti, Guido; Ferrari, Sergio; Kalofonos, Haralabos P, Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study «SUPPORTIVE CARE IN CANCER» , vol. 30 , n. 2 , 2022 , pp. 1807-1814

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo